Lupin is currently trading at Rs. 884.70, up by 13.90 points or 1.60% from its previous closing of Rs. 870.80 on the BSE.
The scrip opened at Rs. 876.00 and has touched a high and low of Rs. 889.15 and Rs. 865.00 respectively. So far 68138 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 955.85 on 15-Jun-2020 and a 52 week low of Rs. 505.00 on 13-Mar-2020.
Last one week high and low of the scrip stood at Rs. 912.95 and Rs. 865.00 respectively. The current market cap of the company is Rs. 39323.77 crore.
The promoters holding in the company stood at 46.92%, while Institutions and Non-Institutions held 39.23% and 13.85% respectively.
Lupin is voluntarily recalling all batches of Metformin Hydrochloride Extended-Release Tablets USP, 500mg and 1000mg products to the consumer level in the U.S. This recall is being conducted out of an abundance of caution in line with the ongoing interaction with the U.S. Food and Drug Administration on NDMA impurity levels. Lupin’s U.S. subsidiary Lupin Pharmaceuticals Inc. distributes Metformin Hydrochloride Extended-Release Tablets USP, 500mg and 1000mg in the U.S.
The company’s Metformin products manufactured and marketed in India have been tested for NDMA levels and have been assessed to be safe for patients and comply with all relevant regulatory norms.
Lupin is an innovation led transnational pharmaceutical company headquartered in Mumbai, India.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1779.40 |
| Dr. Reddys Lab | 1268.75 |
| Cipla | 1376.75 |
| Zydus Lifesciences | 1105.75 |
| Lupin | 2263.40 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: